Cognitive Behavioral Therapy
Published assessmentPublished Oct 7, 2026 · revision 3
Panic Disorder care options
We show care options we have checked for this need. We may not have all options. This page cannot tell you which is best for you.
Published Sep 21, 2026Revision 3 · EveryOptionEnglish (United States)
Published treatment options
These are the options we have published. This order does not say which is best for you.
Assessment for Panic Disorder
Fluoxetine
Published assessmentPublished Sep 20, 2026 · revision 1
Sertraline
Published assessmentPublished Sep 20, 2026 · revision 1
Not reviewed means no current published assessment for the exact pair. No published conclusion means an assessment exists without a research conclusion. Neither establishes benefit or no benefit.
Cognitive Behavioral Therapy for Panic Disorder
This assessment belongs to this exact Treatment and Need. It does not extend its conclusion to other populations or formats.
Research suggests benefit in this exact scope
Published Oct 7, 2026 · revision 3
What research says
NIMH describes cognitive behavioral therapy as a research-supported psychotherapy commonly used for panic disorder. This bounded assessment does not compare every option or determine personal suitability.
NIMH Panic Disorder: What You Need to Know · checked Sep 20, 2026
Relationship: supports bounded conclusion
Statement scope
- Completeness
Not assessed
- Need
Panic Disorder
- Population
source-defined population
Source collection coverage: need:panic-disorder
Pointer: /publication/treatmentExcerpt
Open sourceDelivery and time commitment
Under England’s NICE guideline CG113 (recommendation 1.3.16), CBT for panic disorder in its Step 3 pathway should, for most people, take the form of weekly sessions of 1 to 2 hours, completed within a maximum of 4 months of starting. These are guideline expectations for adults in that pathway; a local provider’s schedule and an individual’s needs may differ.
Official guideline documents · checked Oct 6, 2026
Relationship: supports the attributed weekly session length and maximum course duration
Statement scope
- Delivery
weekly sessions of 1 to 2 hours, completed within a maximum of 4 months of commencement
- Guideline
NICE CG113
- Indication
panic disorder
- Population
most people, under Step 3 for people with panic disorder
- Recommendation year
2004
- Section
Psychological interventions
- Step
Step 3: review and offer alternative treatment if appropriate
Source collection coverage: global
Pointer: /document/passage/text
Open sourceTotal course length
England’s NICE guideline CG113 (recommendation 1.3.15) says CBT for panic disorder in its Step 3 pathway should be offered in the optimal range of 7 to 14 hours in total. This is a guideline expectation for that pathway; a local provider’s schedule and an individual’s needs may differ.
Official guideline documents · checked Oct 7, 2026
Relationship: supports the attributed optimal total CBT duration
Statement scope
- Duration
7 to 14 hours in total
- Guideline
CG113
- Indication
panic disorder
- Intervention class
Psychological interventions
- Population
Adults with panic disorder covered by NICE CG113, within its Step 3 psychological interventions recommendations
- Recommendation
1.3.15
- Recommendation year
2004
- Step
Step 3
Source collection coverage: global
Pointer: /document/passage/text
Open sourceFluoxetine for Panic Disorder
This assessment belongs to this exact Treatment and Need. It does not extend its conclusion to other populations or formats.
Research suggests benefit in this exact scope
Published Sep 20, 2026 · revision 1
What research says
The retained fluoxetine label reports two randomized, placebo-controlled studies for panic disorder; this assessment does not determine personal suitability or compare fluoxetine with every alternative.
DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026
Relationship: supports bounded conclusion
Statement scope
- Jurisdiction
United States label
- Need
Panic Disorder
- Population
source-defined study populations
Source collection coverage: country:US
Pointer: /sections/4
Supporting passage: The effectiveness of fluoxetine in the treatment of Panic Disorder was demonstrated in 2 double-blind, randomized, placebo-controlled, multicenter studies of adult outpatients who had a primary diagnosis of Panic Disorder (DSM-IV), with or without agoraphobia.
Open sourceSertraline for Panic Disorder
This assessment belongs to this exact Treatment and Need. It does not extend its conclusion to other populations or formats.
Research suggests benefit in this exact scope
Published Sep 20, 2026 · revision 1
What research says
The current ZOLOFT label reports three double-blind, placebo-controlled studies in adult outpatients with panic disorder. This bounded assessment does not compare every option or determine personal suitability.
DailyMed sertraline (Zoloft) label · checked Oct 16, 2026
Relationship: supports bounded conclusion
Statement scope
- Completeness
Not assessed
- Need
Panic Disorder
- Population
source-defined population
Source collection coverage: country:US
Pointer: /sections/2
Supporting passage: The effectiveness of ZOLOFT in the treatment of PD was demonstrated in three double‑blind, placebo‑controlled studies (Studies PD-1, PD-2, and PD‑3) of adult outpatients who had a primary diagnosis of PD (DSM‑III‑R), with or without agoraphobia.
Open sourceCoverage
These are the three options EveryOption has published for Panic Disorder: fluoxetine, sertraline, and cognitive behavioral therapy. This is not a complete list of treatments.
NIMH Panic Disorder: What You Need to Know · checked Sep 20, 2026
Relationship: supports published option coverage
Statement scope
- Completeness
Not assessed
- Need
Panic Disorder
- Population
source-defined population
Source collection coverage: need:panic-disorder
Pointer: /publication/treatmentExcerpt
Open sourceDailyMed fluoxetine hydrochloride label · checked Oct 16, 2026
Relationship: supports published option coverage
Statement scope
- Jurisdiction
United States label
- Need
Panic Disorder
- Population
source-defined study populations
Source collection coverage: country:US
Pointer: /sections/4
Supporting passage: The effectiveness of fluoxetine in the treatment of Panic Disorder was demonstrated in 2 double-blind, randomized, placebo-controlled, multicenter studies of adult outpatients who had a primary diagnosis of Panic Disorder (DSM-IV), with or without agoraphobia.
Open sourceDailyMed sertraline (Zoloft) label · checked Oct 16, 2026
Relationship: supports published option coverage
Statement scope
- Completeness
Not assessed
- Need
Panic Disorder
- Population
source-defined population
Source collection coverage: country:US
Pointer: /sections/2
Supporting passage: The effectiveness of ZOLOFT in the treatment of PD was demonstrated in three double‑blind, placebo‑controlled studies (Studies PD-1, PD-2, and PD‑3) of adult outpatients who had a primary diagnosis of PD (DSM‑III‑R), with or without agoraphobia.
Open sourceAccess
These are the options and access paths EveryOption has published for Denver for Panic Disorder. This is not complete coverage of the condition or the city.
Provider-owned websites · checked Sep 20, 2026
Relationship: supports Denver access navigation
Statement scope
- Geography
Denver, Colorado, United States
- Need
Panic Disorder
- Treatment
Cognitive Behavioral Therapy
Source collection coverage: global
Pointer: /statements/0/text
Open sourceFind care
Open the published Denver result for this Need and treatment. It is one sourced path, not complete coverage or a statement of current availability.
You can also look for documented medication evaluation or ongoing management for Panic Disorder, without selecting a specific medication.
Find medication servicesPublished relationship sources
These sources explain why each Treatment is listed for this Need. They are separate from its exact-pair assessment.
Cognitive Behavioral Therapy for Panic Disorder
NIMH Panic Disorder: What You Need to Know · checked Sep 20, 2026
Relationship: source-described CBT relationship for the Need
Statement scope
- Completeness
Not assessed
- Need
Panic Disorder
- Population
source-defined population
Source collection coverage: need:panic-disorder
Pointer: /publication/treatmentExcerpt
Open sourceFluoxetine for Panic Disorder
DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026
Relationship: label-reported clinical studies for the Need
Statement scope
- Jurisdiction
United States label
- Need
Panic Disorder
- Population
source-defined study populations
Source collection coverage: country:US
Pointer: /sections/4
Supporting passage: The effectiveness of fluoxetine in the treatment of Panic Disorder was demonstrated in 2 double-blind, randomized, placebo-controlled, multicenter studies of adult outpatients who had a primary diagnosis of Panic Disorder (DSM-IV), with or without agoraphobia.
Open sourceSertraline for Panic Disorder
DailyMed sertraline (Zoloft) label · checked Oct 16, 2026
Relationship: label-reported clinical studies for the Need
Statement scope
- Completeness
Not assessed
- Need
Panic Disorder
- Population
source-defined population
Source collection coverage: country:US
Pointer: /sections/2
Supporting passage: The effectiveness of ZOLOFT in the treatment of PD was demonstrated in three double‑blind, placebo‑controlled studies (Studies PD-1, PD-2, and PD‑3) of adult outpatients who had a primary diagnosis of PD (DSM‑III‑R), with or without agoraphobia.
Open sourceSee something wrong? Tell us. Your note is private. We check sources before we change this page.